Acadia Pharmaceuticals Stock Beneish M Score
| ACAD Stock | USD 17.05 0.03 0.18% |
ACADIA | Beneish M Score |
At this time, ACADIA Pharmaceuticals' M Score is unavailable. The earnings manipulation may begin if ACADIA Pharmaceuticals' top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by ACADIA Pharmaceuticals executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of ACADIA Pharmaceuticals' earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-3.14
Beneish M Score - Unavailable
ACADIA Pharmaceuticals Beneish M-Score Indicator Trends
The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if ACADIA Pharmaceuticals' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Net Receivables | 107.5 M | 102.3 M |
|
| |||||
| Total Revenue | 762.8 M | 726.4 M |
|
| |||||
| Total Assets | 786.4 M | 749 M |
|
| |||||
| Total Current Assets | 646.9 M | 616.1 M |
|
| |||||
| Non Current Assets Total | 139.5 M | 132.8 M |
|
| |||||
| Property Plant Equipment | 74.4 M | 70.8 M |
|
| |||||
| Depreciation And Amortization | 5.8 M | 5.6 M |
|
| |||||
| Selling General Administrative | 412.7 M | 393.1 M |
|
| |||||
| Total Current Liabilities | 267 M | 254.3 M |
|
| |||||
| Non Current Liabilities Total | 66.1 M | 62.9 M |
|
| |||||
| Short Term Debt | 9.9 M | 9.4 M |
|
| |||||
| Short Term Investments | 185.1 M | 250.2 M |
|
| |||||
| Long Term Investments | 2 M | 2.6 M |
|
| |||||
| Gross Profit Margin | 0.74 | 0.937 |
|
|
ACADIA Pharmaceuticals Beneish M-Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between ACADIA Pharmaceuticals' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards ACADIA Pharmaceuticals in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find ACADIA Pharmaceuticals' degree of accounting gimmicks and manipulations.
Click cells to compare fundamentals
About ACADIA Pharmaceuticals Beneish M Score
M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.
Depreciation And Amortization |
|
ACADIA Pharmaceuticals Earnings Manipulation Drivers
Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as ACADIA Pharmaceuticals. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Receivables | 37.9M | 50.3M | 65.3M | 63.1M | 102.4M | 107.5M | |
| Total Revenue | 339.1M | 441.8M | 484.1M | 517.2M | 726.4M | 762.8M | |
| Total Assets | 783.2M | 782.6M | 700.1M | 587.8M | 749.0M | 786.4M | |
| Total Current Assets | 760.3M | 717.6M | 617.8M | 507.9M | 616.1M | 646.9M | |
| Net Debt | (183.3M) | (281.6M) | (91.3M) | (52.8M) | (131.5M) | (124.9M) | |
| Operating Income | (246.5M) | (286.6M) | (170.4M) | (223.6M) | (73.4M) | (77.0M) | |
| Investments | (164.7M) | 200.1M | (70.0M) | 73.2M | 32.0M | 33.6M | |
| Gross Profit Margin | 0.92 | 0.94 | 0.95 | 0.96 | 0.98 | 0.74 |
About ACADIA Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ACADIA Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ACADIA Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ACADIA Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
ACADIA Pharmaceuticals Investors Sentiment
The influence of ACADIA Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in ACADIA. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to ACADIA Pharmaceuticals' public news can be used to forecast risks associated with an investment in ACADIA. The trend in average sentiment can be used to explain how an investor holding ACADIA can time the market purely based on public headlines and social activities around ACADIA Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
ACADIA Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for ACADIA Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average ACADIA Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on ACADIA Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ACADIA Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ACADIA Pharmaceuticals' short interest history, or implied volatility extrapolated from ACADIA Pharmaceuticals options trading.
Pair Trading with ACADIA Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ACADIA Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ACADIA Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with ACADIA Stock
| 0.73 | EGRX | Eagle Pharmaceuticals Earnings Call This Week | PairCorr |
| 0.66 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
Moving against ACADIA Stock
| 0.79 | SNDL | SNDL Inc Earnings Call This Week | PairCorr |
| 0.74 | CGC | Canopy Growth Corp Financial Report 27th of June 2024 | PairCorr |
| 0.72 | QLI | Qilian International | PairCorr |
| 0.7 | IMCC | Im Cannabis Corp Earnings Call This Week | PairCorr |
| 0.52 | PAHC | Phibro Animal Health Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to ACADIA Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ACADIA Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ACADIA Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ACADIA Pharmaceuticals to buy it.
The correlation of ACADIA Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ACADIA Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ACADIA Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ACADIA Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out ACADIA Pharmaceuticals Piotroski F Score and ACADIA Pharmaceuticals Altman Z Score analysis. For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.Note that the ACADIA Pharmaceuticals information on this page should be used as a complementary analysis to other ACADIA Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for ACADIA Stock analysis
When running ACADIA Pharmaceuticals' price analysis, check to measure ACADIA Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ACADIA Pharmaceuticals is operating at the current time. Most of ACADIA Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ACADIA Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ACADIA Pharmaceuticals' price. Additionally, you may evaluate how the addition of ACADIA Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |
Is ACADIA Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACADIA Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.37) | Revenue Per Share 4.434 | Quarterly Revenue Growth 0.693 | Return On Assets (0.07) | Return On Equity (0.15) |
The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACADIA Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ACADIA Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACADIA Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.